关注
Ricardo Correa-Rotter
Ricardo Correa-Rotter
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City Mexico
在 incmnsz.mx 的电子邮件经过验证
标题
引用次数
引用次数
年份
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
RSI Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Parving HH, Remuzzi G ...
New England Journal of Medicine 345 (12), 861-869, 2001
96572001
Dapagliflozin in patients with chronic kidney disease
HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, ...
New England Journal of Medicine 383 (15), 1436-1446, 2020
37472020
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ...
The Lancet 382 (9889), 339-352, 2013
23972013
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
KG Saag, R Emkey, TJ Schnitzer, JP Brown, F Hawkins, S Goemaere, ...
New England Journal of Medicine 339 (5), 292-299, 1998
15941998
Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial
R Paniagua, D Amato, E Vonesh, R Correa-Rotter, A Ramos, J Moran, ...
Journal of the American Society of Nephrology 13 (5), 1307-1320, 2002
13112002
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis
EVOLVE Trial Investigators
New England Journal of Medicine 367 (26), 2482-2494, 2012
10362012
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ...
The Lancet 390 (10105), 1888-1917, 2017
9212017
Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial
JD Adachi, KG Saag, PD Delmas, UA Liberman, RD Emkey, E Seeman, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2001
7182001
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
5092019
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis
JJ Body, GA Gaich, WH Scheele, PM Kulkarni, PD Miller, A Peretz, ...
The Journal of Clinical Endocrinology & Metabolism 87 (10), 4528-4535, 2002
4532002
CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy
R Correa-Rotter, C Wesseling, RJ Johnson
American journal of kidney diseases 63 (3), 506-520, 2014
4322014
Climate change and the emergent epidemic of CKD from heat stress in rural communities: the case for heat stress nephropathy
J Glaser, J Lemery, B Rajagopalan, HF Diaz, R García-Trabanino, ...
Clinical Journal of the American Society of Nephrology 11 (8), 1472-1483, 2016
4202016
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the …
DC Wheeler, BV Stefánsson, N Jongs, GM Chertow, T Greene, FF Hou, ...
The lancet Diabetes & endocrinology 9 (1), 22-31, 2021
3582021
Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block, R Correa-Rotter, ...
Circulation 132 (1), 27-39, 2015
3082015
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy
D De Zeeuw, B Coll, D Andress, JJ Brennan, H Tang, M Houser, ...
Journal of the American Society of Nephrology 25 (5), 1083-1093, 2014
3082014
Fructokinase activity mediates dehydration-induced renal injury
CAR Jimenez, T Ishimoto, MA Lanaspa, CJ Rivard, T Nakagawa, AA Ejaz, ...
Kidney international 86 (2), 294-302, 2014
2852014
Dissonant health transition in the states of Mexico, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
H Gómez-Dantés, N Fullman, H Lamadrid-Figueroa, L Cahuana-Hurtado, ...
The Lancet 388 (10058), 2386-2402, 2016
2782016
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
JP Devogelaer, H Broll, R Correa-Rotter, DC Cumming, ...
Bone 18 (2), 141-150, 1996
2561996
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
DC Wheeler, RD Toto, BV Stefansson, N Jongs, GM Chertow, T Greene, ...
Kidney international 100 (1), 215-224, 2021
2372021
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot, PJ Meunier, G Boivin, L Haddock, J Tamayo, R Correa‐Rotter, ...
Journal of Bone and Mineral Research 20 (7), 1244-1253, 2005
2332005
系统目前无法执行此操作,请稍后再试。
文章 1–20